Citrinin as a potential anti-cancer therapy: A comprehensive review

Chem Biol Interact. 2023 Aug 25:381:110561. doi: 10.1016/j.cbi.2023.110561. Epub 2023 May 23.

Abstract

Citrinin (CIT) is a polyketide-derived mycotoxin, which is produced by many fungal strains belonging to the gerena Monascus, Aspergillus, and Penicillium. It has been postulated that mycotoxins have several toxic mechanisms and are potentially used as antineoplastic agents. Therefore, the present study carried out a systematic review, including articles from 1978 to 2022, by collecting evidence in experimental studies of CIT antiplorifactive activity in cancer. The Data indicate that CIT intervenes in important mediators and cell signaling pathways, including MAPKs, ERK1/2, JNK, Bcl-2, BAX, caspases 3,6,7 and 9, p53, p21, PARP cleavage, MDA, reactive oxygen species (ROS) and antioxidant defenses (SOD, CAT, GST and GPX). These factors demonstrate the potential antitumor drug CIT in inducing cell death, reducing DNA repair capacity and inducing cytotoxic and genotoxic effects in cancer cells.

Keywords: Antiplorifactive mechanisms; Cytotoxicity; Genotoxicity; Mycotoxins; Toxicity.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Cell Death
  • Cell Lineage
  • Citrinin / therapeutic use
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Citrinin